FDA requires GLP-1 drug labels to warn of rare eye condition linked to vision loss

The U.S. Food and Drug Administration announced on Nov. 9, 2026, that makers of all GLP-1 drugs must add a warning label about a potential link to a rare eye condition that can result in vision loss.

What the FDA found

The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION, and doctors often refer to it as a stroke of the eye. It is an injury to the optic nerve caused by a sudden reduction in blood flow. Symptoms can include sudden, painless blurry vision, dark patches, partial loss of vision or even blindness. These symptoms generally persist and often lead to permanent visual impairment.

The FDA said "there is a potential increased risk of rare NAION" in people taking GLP-1 drugs. The agency reviewed 126 randomized, controlled clinical trials of GLP-1 drugs that included a total of 134,253 patients. Per year, on average, the incidence of NAION cases was 6.4 per 100,000 people for patients taking the GLP-1 drugs and 3.8 per 100,000 among people given a placebo or a different medication.

The FDA also reviewed real-world data from its sentinel programs. Patients taking GLP-1 drugs experienced NAION at a rate of 32 per 100,000 over one year, compared with 26 per 100,000 for those taking DPP-4 inhibitors, resulting in 6 extra cases per 100,000 patients.

Which drugs are affected

The requirement applies to all GLP-1s, including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, as well as several older GLP-1 diabetes medications. The Guardian reported the requirement also covers Sanofi’s Soliqua.

Spokespeople for both Novo Nordisk and Eli Lilly said patient safety is their top priority. A Novo Nordisk spokesperson told the Guardian that the company "continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines."

What patients should know

NAION is the second most common optic nerve disease in the U.S., occurring in up to 10 out of 100,000 people over age 50, according to the American Academy of Ophthalmology. There is no known treatment to reverse vision loss from NAION.

Dr. Manjot Gill, an ophthalmologist at Northwestern Medicine in Chicago, said the FDA’s mandate for a warning label was appropriate. "We don’t want patients to really get overly concerned and anxious and to stop these medications," Gill said. "It’s fine to issue this warning more so for public awareness so that patients, should they experience any kind of change in vision, that they do actually go and seek the care of an eye provider."

Why it matters

Millions of people take GLP-1 drugs to treat diabetes and obesity. The FDA’s warning means patients and clinicians should discuss the potential risk before prescribing, and patients should seek immediate care at the earliest signs of vision problems. The agency said it was not able to identify a mechanism for how the drugs could increase the risk of the eye condition, and some studies have found no correlation between GLP-1 use and NAION.

---

Sources

• theconversation.com: GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect
• nbcnews.com: FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
• theguardian.com: FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications | US news | The Guardian
• finance.yahoo.com: FDA warns about alarming eye risk with GLP-1 drugs after dozens sue over vision loss tied to the medication
• arstechnica.com: FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss - Ars Technica
• everydayhealth.com: Risk of Vision Loss Prompts FDA to Require Warning on GLP-1 Drugs

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.